Brief Report: Body Mass Index and Cognitive Function Among HIV-1-Infected Individuals in China, India, and Nigeria.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
pubmed:
14
11
2018
medline:
31
10
2019
entrez:
14
11
2018
Statut:
ppublish
Résumé
Risk of cognitive impairment is increased among persons with high or low body mass index in HIV- and HIV+ populations in resource-rich settings. We examined this association among HIV+ patients in 3 resource-limited settings. This secondary analysis included data of 761 HIV+ volunteers pooled from 3 prospective cohort studies conducted in China (n = 404; 53%), India (n = 200; 26%), and Nigeria (n = 157; 21%). World Health Organization (WHO) weight classifications were based on body mass index. T scores, adjusted for demographics and practice effects, were derived from a 7-domain neuropsychological battery. Neurocognitive impairment (NCI) was defined as global deficit score of ≥0.5. Overall, prevalence of NCI at baseline was 27.7% (similar across all cohorts). The overweight/obese and underweight constituted 37.3% and 15.5% of the total participants, respectively. In a multivariable logistic regression of pooled longitudinal data, adjusting for clinical and demographic variables, the odds of global NCI were 38% higher among the overweight/obese as compared to normal weight participants [odds ratio: 1.38 (95% confidence interval: 1.1 to 1.72); P = 0.005]. Similarly, the odds of global NCI were 39% higher among the underweight as compared to normal weight participants [odds ratio: 1.39 (95% confidence interval: 1.03 to 1.87); P = 0.029]. NCI among HIV-1-infected patients was more prevalent in both overweight/obese and underweight than normal weight individuals in 3 resource-limited settings, confirming observations in resource-rich settings. Mechanisms underlying these associations are unclear but likely differ for underweight and overweight persons.
Sections du résumé
BACKGROUND
Risk of cognitive impairment is increased among persons with high or low body mass index in HIV- and HIV+ populations in resource-rich settings. We examined this association among HIV+ patients in 3 resource-limited settings.
METHODS
This secondary analysis included data of 761 HIV+ volunteers pooled from 3 prospective cohort studies conducted in China (n = 404; 53%), India (n = 200; 26%), and Nigeria (n = 157; 21%). World Health Organization (WHO) weight classifications were based on body mass index. T scores, adjusted for demographics and practice effects, were derived from a 7-domain neuropsychological battery. Neurocognitive impairment (NCI) was defined as global deficit score of ≥0.5.
RESULTS
Overall, prevalence of NCI at baseline was 27.7% (similar across all cohorts). The overweight/obese and underweight constituted 37.3% and 15.5% of the total participants, respectively. In a multivariable logistic regression of pooled longitudinal data, adjusting for clinical and demographic variables, the odds of global NCI were 38% higher among the overweight/obese as compared to normal weight participants [odds ratio: 1.38 (95% confidence interval: 1.1 to 1.72); P = 0.005]. Similarly, the odds of global NCI were 39% higher among the underweight as compared to normal weight participants [odds ratio: 1.39 (95% confidence interval: 1.03 to 1.87); P = 0.029].
CONCLUSIONS
NCI among HIV-1-infected patients was more prevalent in both overweight/obese and underweight than normal weight individuals in 3 resource-limited settings, confirming observations in resource-rich settings. Mechanisms underlying these associations are unclear but likely differ for underweight and overweight persons.
Identifiants
pubmed: 30422905
doi: 10.1097/QAI.0000000000001906
pmc: PMC6331248
mid: NIHMS1510574
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30-e35Subventions
Organisme : NIMH NIH HHS
ID : R01 MH078748
Pays : United States
Organisme : BLRD VA
ID : I01 BX003222
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH086356
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW001041
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA044908
Pays : United States
Références
Neurology. 2012 Feb 14;78(7):485-92
pubmed: 22330412
Int J Clin Pract. 2010 Dec;64(13):1808-12
pubmed: 21070531
JAMA. 2004 Nov 10;292(18):2237-42
pubmed: 15536110
Curr Alzheimer Res. 2007 Apr;4(2):111-6
pubmed: 17430232
J Gerontol A Biol Sci Med Sci. 2010 Jan;65(1):57-62
pubmed: 19349594
Neurology. 2006 Oct 10;67(7):1208-14
pubmed: 17030754
Epidemiol Rev. 2013;35:22-32
pubmed: 23258415
J Neuroimmune Pharmacol. 2013 Dec;8(5):1123-35
pubmed: 24101401
Circulation. 2008 Apr 1;117(13):1658-67
pubmed: 18362231
J Neurovirol. 2018 Dec;24(6):712-719
pubmed: 30168015
J Clin Exp Neuropsychol. 2004 May;26(3):307-19
pubmed: 15512922
Int J Obes Relat Metab Disord. 2003 Feb;27(2):260-8
pubmed: 12587008
AIDS. 2010 Jun 1;24(9):1367-70
pubmed: 20559041
J Neurovirol. 2015 Aug;21(4):391-8
pubmed: 25750072
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Stroke. 2011 Sep;42(9):2672-713
pubmed: 21778438
Biochim Biophys Acta. 2009 May;1792(5):470-81
pubmed: 18848880
Front Genet. 2013 Jan 28;3:328
pubmed: 23372574
Curr Opin Investig Drugs. 2010 Aug;11(8):884-900
pubmed: 20721831
N Engl J Med. 1992 Jul 30;327(5):329-37
pubmed: 1620172
Lancet Diabetes Endocrinol. 2015 Jun;3(6):431-436
pubmed: 25866264
Obes Rev. 2008 May;9(3):204-18
pubmed: 18331422
Am J Epidemiol. 1999 Jun 1;149(11):981-3
pubmed: 10355372
Int J Obes (Lond). 2015 Sep;39(9):1383-9
pubmed: 25953125
AIDS. 2011 Sep 10;25(14):1747-51
pubmed: 21750419
J Int Neuropsychol Soc. 2002 Mar;8(3):410-24
pubmed: 11939699
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):281-8
pubmed: 25469522
Am J Clin Nutr. 2006 Feb;83(2):461S-465S
pubmed: 16470013
Clin Neuropsychol. 2012;26(6):894-908
pubmed: 22708483
Am J Clin Nutr. 2009 Feb;89(2):601-7
pubmed: 19073790
Eur J Cardiovasc Nurs. 2015 Aug;14(4):334-41
pubmed: 24829294
Diabetes Care. 2013 Aug;36 Suppl 2:S276-81
pubmed: 23882059
Diabetol Metab Syndr. 2013 Jun 27;5(1):31
pubmed: 23806173
Neurobiol Aging. 2009 Aug;30(8):1177-83
pubmed: 18077061
Neurosci Biobehav Rev. 2009 Mar;33(3):355-66
pubmed: 18996146
PLoS One. 2014 Dec 17;9(12):e114424
pubmed: 25517735
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):557-61
pubmed: 16044007
AIDS. 2013 Jun 1;27(9):1387-95
pubmed: 23435298
PLoS One. 2013 May 29;8(5):e63999
pubmed: 23734182
Scand J Psychol. 2009 Dec;50(6):660-7
pubmed: 19930267
Lancet Neurol. 2006 Aug;5(8):713-20
pubmed: 16857578
AIDS Patient Care STDS. 2008 Dec;22(12):925-30
pubmed: 19072098
Eur J Pharmacol. 2008 May 6;585(1):97-108
pubmed: 18395201
PLoS One. 2016 Feb 11;11(2):e0148908
pubmed: 26867138
Biochimie. 2012 Oct;94(10):2137-42
pubmed: 22713764
Dement Geriatr Cogn Disord. 2010;29(6):543-52
pubmed: 20606436
J Neurovirol. 2013 Dec;19(6):574-85
pubmed: 24338243
Neurology. 2010 Sep 7;75(10):864-73
pubmed: 20702792
Neuropsychol Rev. 2009 Jun;19(2):152-68
pubmed: 19462243
Int Rev Psychiatry. 2008 Feb;20(1):25-31
pubmed: 18240060
Front Neurosci. 2014 Nov 19;8:375
pubmed: 25477778
Nat Rev Neurosci. 2001 Oct;2(10):734-44
pubmed: 11584311
Neuroepidemiology. 2010;34(4):222-9
pubmed: 20299802
J Neurovirol. 2008 Nov;14(6):536-49
pubmed: 18991068
Int J Obes (Lond). 2008 Jun;32(6):959-66
pubmed: 18283284
Hypertens Res. 2010 May;33(5):386-93
pubmed: 20442753
PLoS One. 2016 Feb 01;11(2):e0147182
pubmed: 26829391
Obes Rev. 2011 May;12(5):e426-37
pubmed: 21348917
J Neurovirol. 2016 Apr;22(2):246-50
pubmed: 26306690
Ann Intern Med. 2000 Oct 17;133(8):622-34
pubmed: 11033592